Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IXQ5
UPID:
KLHL7_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IXQ5; A4D144; B7Z5I9; G5E9G3; Q7Z765; Q96MV2; Q9BQF8; Q9UDQ9
Background:
Kelch-like protein 7 functions as a substrate-specific adapter in a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex, mediating ubiquitination and degradation of proteins. This process is crucial for maintaining cellular homeostasis.
Therapeutic significance:
Kelch-like protein 7 is implicated in Perching syndrome and Retinitis pigmentosa 42, diseases characterized by developmental delays, retinal dystrophy, and more. Targeting this protein could lead to novel treatments for these conditions.